Tetra Bio-Pharma subsidiary Agro-Tek has signed an exclusive supply and distribution agreement with Engen Medical Corporation to distribute Engen’s Munchies B Gone gum in Canada.

Agro-Tek will have exclusive sales and distribution rights for the product in Canada for five years, under the agreement.

US-based Engen Medical Corporation owns global patent and intellectual property rights to a number of chewing gum products.

Canadian biopharmaceutical company ProMetic Life Sciences has raised C$21.05m ($16.13m) through the private placement of 4.4 million shares upon exercise of warrants by California Capital Equity.

The placement was priced at C$0.47 ($0.36) a share.

"UK-based biotechnology company Nemaura Pharma has announced that it will raise £5m ($6.24m) in equity financing from private investors."

UK-based biotechnology company Nemaura Pharma has announced that it will raise £5m ($6.24m) in equity financing from private investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to use the funds to advance its Micro-Patch solid dose micro-needle system for a harmonic biologic, while part of them will also help accelerate its clinical programmes to prepare the drug-device combination for the market.

Canadian immunotherapy company Medicenna Therapeutics has announced that it intends to raise C$3.6m ($2.76m) in gross proceeds through a private placement of 1.8 million shares of its common stock in order to fund its non-clinical and clinical programmes, as well as meet working capital and general corporate needs.

The shares are priced at C$2 ($1.5) each.